Rocket Pharmaceuticals Files Schedule TO for Option Exchange

Rocket Pharmaceuticals, Inc. filed a Schedule TO tender offer statement with the SEC as an issuer tender offer under Rule 13e-4. The filing relates to proposed stock option exchange program communications sent to employees on April 1, 2026.

The proposed Exchange Program would allow current employees who are not executive officers at the EVP level or above to exchange certain stock options with per-share exercise prices at or above the trading price immediately prior to commencement. The exchange is described as approximately value-neutral, and the program has not yet commenced. Rocket Pharmaceuticals states it may decide not to implement the Exchange Program and will file a Schedule TO if and when the program begins.